An Allyl Protection and Improved Purification Strategy Enables the Synthesis of Functionalized Phosphonamidate Peptides
作者:Gerhard Klebe、Jonathan Cramer
DOI:10.1055/s-0036-1588393
日期:——
biophysical methods such as isothermal titration calorimetry, high purity of the inhibitor of interest is indispensable. Herein, we describe a procedure for the synthesis and purification of functionalized phosphonamidate peptides that is able to generate inhibitors for the metalloprotease thermolysin for use in biophysical experiments. The method utilizes an allyl ester/alloc protection strategy and
Capturing Intermediates in the Reaction Catalyzed by NosN, a Class C Radical <i>S</i>-Adenosylmethionine Methylase Involved in the Biosynthesis of the Nosiheptide Side-Ring System
作者:Bo Wang、Joseph W. LaMattina、Savannah L. Marshall、Squire J. Booker
DOI:10.1021/jacs.8b13157
日期:2019.4.10
of Glu6 of the core peptide and the nascent C1 unit. However, exactly when NosN performs its function during the biosynthesis of nosiheptide is unknown. Herein, we report the syntheses and use of three peptidemimics as potential substrates designed to address the timing of NosN's function. Our results show that NosN clearly closes the side ring before NosO forms the pyridine ring and most likely before
[EN] METHODS AND COMPOSITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS
申请人:RES & INNOVATION UK
公开号:WO2020084307A1
公开(公告)日:2020-04-30
The invention relates to genetic incorporation of 2,3-diamino propionic acid (DAP) into polypeptides, to unnatural amino acids comprising DAP, to a tRNA synthetase for charging tRNA with unnatural amino acids comprising DAP, and to methods of using the resulting polypeptides, for example in capturing substrates and/or intermediates in enzymatic reactions. The invention also relates to compounds of formula (I) or (II): or salts, solvates, tautomers, isomers or mixtures thereof.
Compounds That Inhibit Replication Of Human Immunodeficiency Virus
申请人:Balzarini Maria Rene Jan
公开号:US20080076824A1
公开(公告)日:2008-03-27
The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.